PULIKE BIOLOGICAL ENGINEERING, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.84 CNY | +0.28% |
|
+5.25% | -21.24% |
| Sales 2023 * | 1.37B 190M | Sales 2024 * | 1.6B 220M | Capitalization | 6.05B 835M |
|---|---|---|---|---|---|
| Net income 2023 * | 244M 33.67M | Net income 2024 * | 319M 44.02M | EV / Sales 2023 * | 3.7 x |
| Net cash position 2023 * | 967M 133M | Net cash position 2024 * | 1.03B 142M | EV / Sales 2024 * | 3.14 x |
| P/E ratio 2023 * |
25.7
x | P/E ratio 2024 * |
19.7
x | Employees | 1,718 |
| Yield 2023 * |
2.8% | Yield 2024 * |
3.6% | Free-Float | 51.44% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.28% | ||
| 1 week | +5.25% | ||
| Current month | +2.23% | ||
| 1 month | +4.39% | ||
| 3 months | +5.69% | ||
| 6 months | -7.85% | ||
| Current year | -21.24% |
1 week
16.92
18.20
1 month
16.3318.72
Current year
12.8922.85
1 year
12.8928.80
3 years
12.8934.90
5 years
11.3334.90
10 years
10.5843.25
| Managers | Title | Age | Since |
|---|---|---|---|
Fei Hu
CEO | Chief Executive Officer | 51 | - |
Lian Feng Pei
DFI | Director of Finance/CFO | 51 | 11-03-22 |
Rui Zhao
BRD | Director/Board Member | 40 | 16-05-03 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Xian Sheng Zhang
BRD | Director/Board Member | 59 | 23-04-10 |
Fei Hu
CEO | Chief Executive Officer | 51 | - |
Xu Ke Zhang
CHM | Chairman | 61 | 11-03-22 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-24 | 17.84 | +0.28% | 1,801,400 |
| 24-04-23 | 17.79 | -1.44% | 2,005,800 |
| 24-04-22 | 18.05 | +2.73% | 2,606,300 |
| 24-04-19 | 17.57 | +2.75% | 2,366,800 |
| 24-04-18 | 17.1 | +0.88% | 2,075,600 |
End-of-day quote Shanghai S.E., April 23, 2024
More quotes
Pulike Biological Engineering. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The Company's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.
Sector
Pharmaceuticals
Calendar
2024-04-25
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.84
CNY
Average target price
22.6
CNY
Spread / Average Target
+26.68%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -21.24% | 835M | |
| -10.67% | 6.56B | |
| +16.00% | 3.43B | |
| +0.14% | 3.22B | |
| +2.53% | 1.46B | |
| -14.67% | 1.38B | |
| -2.44% | 1.26B | |
| -27.57% | 1.21B | |
| -12.86% | 1.14B | |
| -2.99% | 1.02B |
- Stock Market
- Equities
- 603566 Stock
